GLP1R and diabetes mellitus: The GLP-1R agonists liraglutide and lixisenatide were selected because topical formulations of both as well as systemic administration of liraglutide demonstrated effectiveness against retinal neurodegeneration in a mouse model of diabetes (Hernández et al., 2016).